UPB UPSTREAM BIO INC

Upstream Bio to Present at Upcoming March Investor Conferences

Upstream Bio to Present at Upcoming March Investor Conferences

WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Upstream Bio’s CEO, will present at the following upcoming March investor conferences:

  • TD Cowen 45th Annual Health Care Conference, Boston MA

    Tuesday, March 4, 2025, 11:50 a.m. – 12:20 p.m. ET
  • Leerink Partners Global Biopharma Conference 2025, Miami FL

    Wednesday, March 12, 2025, 1:40 p.m. – 2:10 p.m. ET

A live webcast of the presentation will be available under the tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be posted on the Company's website following the presentation.

About Upstream Bio

Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit .

Investor Contact:

Michael Gray

Chief Financial Officer and Chief Operating Officer

Media Contact:

Teri Dahlman

Red House Communications



EN
25/02/2025

Underlying

UPBUPSTREAM BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on UPSTREAM BIO INC

 PRESS RELEASE
Free
UPB UPSTREAM BIO IN...

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIAN...

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma – Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also delivered clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO) with both dose regimens – – Verekitug was generally well tolerated, with a safety profile consistent with prior studies – – Over 90% of eligible patients have rolled over to t...

February 11, 2026 1 EN
 PRESS RELEASE
Free
UPB UPSTREAM BIO IN...

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase...

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma – Webcast to be held Wednesday, February 11, 2026, at 8:00 a.m. ET – WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line results from the Phase 2 VALIANT trial of verekitug, the only known antagonist currently in clinical development that targets and inhibits the thymic stromal...

February 10, 2026 1 EN
 PRESS RELEASE
Free
UPB UPSTREAM BIO IN...

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conf...

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 2:15 p.m. PT. A live webcast of the presentation will be available under the  tab on the Investors section of Upstream Bio’s website on...

January 5, 2026 1 EN
 PRESS RELEASE
Free
UPB UPSTREAM BIO IN...

Upstream Bio to Participate in Upcoming December Investor Conferences

Upstream Bio to Participate in Upcoming December Investor Conferences WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in December: Piper Sandler 37th Annual Healthcare Conference, New York, NYTuesday, December 2, 2025, Fireside Chat – 4:30 p.m. ET8th Annual Evercore Healthcare Conference, Miami...

November 25, 2025 1 EN
 PRESS RELEASE
Free
UPB UPSTREAM BIO IN...

Upstream Bio Reports Third Quarter 2025 Financial Results and Highligh...

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress – Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary endpoints when administered once every 12 weeks – – On-track to report top-line results from VALIANT Phase 2 trial in severe asthma in the first quarter of 2026 – – Enrollment ongoing in VENTURE Phase 2 trial in COPD; first patient dosed in July – WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (Nasd...

November 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch